SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
SpringWorks Therapeutics (SWTX) reported a Q4 loss of $1.04 per share, which was larger than the Zacks Consensus Estimate of a $0.72 loss. However, the company exceeded revenue expectations.
February 20, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
SpringWorks Therapeutics reported a Q4 loss of $1.04 per share, missing the Zacks Consensus Estimate of a $0.72 loss. Despite the larger loss, the company exceeded revenue expectations.
The larger-than-expected loss per share is likely to negatively impact SWTX's stock price in the short term, despite the positive news of exceeding revenue expectations. Investors often react more strongly to earnings per share results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100